ReviewPubMed ID: 20738209·2010

Thymosin alpha-1 safety profile: adverse events across 50+ clinical trials

Harley CB, Goldstein AL, Tuthill CW.

Current Aging Science, 2010

Key finding

Excellent safety profile; injection site reactions (15%), mild systemic symptoms (flu-like, 8%); no serious organ toxicity or dose-limiting events.

Summary

Comprehensive safety review of thymosin alpha-1 across >50 clinical trials encompassing >1000 patients over 30+ years.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

Thymosin Alpha-1L4

A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.

More research on Thymosin Alpha-1

COVID-19 immunotherapy: thymosin alpha-1 efficacy in severe disease

Cytokine · 2021 · Human RCT

Combination immunotherapy: thymosin alpha-1 with checkpoint inhibitors in cancer

Journal for ImmunoTherapy of Cancer · 2020 · Human Pilot

Thymalfasin: clinical pharmacology and antiviral applications

BioDrugs · 2010 · Review

Thymosin alpha-1 and thymic regeneration in aging

Nature Immunology · 2009 · Animal Study

TNF-α and IL-2 modulation by thymosin alpha-1 in immune cells

Molecular Immunology · 2005 · In Vitro